 EMERYVILLE, Calif.--BUSINESS WIRE--Adamas Pharmaceuticals, Inc. Nasdaq: ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announces the issuance of two patents covering GOCOVRI amantadine extended-release capsules: U.S. Patent No. 11,065,213 issued on July 20, 2021, and U.S. Patent No. 11,077,073, projected to issue on August 3, 2021. These two patents are the first issued in this patent f 